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http://dx.doi.org/10.1016/j.jmii.2012Background/Purpose(s): To explore the clinical features of different human metapneumovirus
(hMPV) genotypes/genogroups in hospitalized children.
Methods: From January 2005 to April 2010, 3313 children’s respiratory specimens sent for the
detection of respiratory syncytial virus antigen were also tested for hMPV by real time-
polymerase chain reaction. Demographics, clinical presentations, and laboratory findings of
patients infected with different genotypes/genogroups of hMPV were compared.
Results: A total of 725 samples were positive for hMPV (positive rate, 23%). The F gene was
sequencedfor279 isolates; of these,genotypeAwas identified in51%(A1,6.1%;A2,45%) andgeno-
type B in 49% (B1, 19%; B2, 30%). Medical records of 152 hospitalized children were reviewed.
Co-infection with other pathogens was 25.7% (39/152). Excluding co-pathogens other than respi-
ratory syncytial virus, a total of 124childrenwereanalyzed.Themost commonsymptoms included
cough, fever, rhinorrhea, wheezing and respiratory distress with accessory muscle usage. The
main diagnosis was bronchiolitis. The most common chest radiographic findings were increased
perihilar infiltrates. No significant difference was found in terms of demographics, clinical mani-
festations, and laboratoryfindings among thechildren infectedwithdifferent serogroupsofhMPV.
Conclusion: hMPVaccounted fora substantialproportionofhospitalizedchildrenwith lower respi-
ratory tract infection with a high co-infection rate. The A2 subgroup was the most frequentlyediatric Infectious Diseases, Department of Pediatrics, Chang Gung Children’s Hospital, No. 5, Fu-Shin
n.
h.org.tw (Y.-C. Huang).
qually to this work.
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Clinical features of hMPV genotypes/genogroups 353observed, followed by B2. No significant difference was found among patients infected
with different genotypes/genogroups of hMPV in terms of clinical manifestations.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Human metapneumovirus (hMPV) is a newly identified
pathogen associated with acute respiratory tract infection
first discovered by van den Hoogen et al1 in 2001. After-
ward, hMPV was found worldwide. Studies from Europe,
North America, and Asia have indicated hMPV can cause
respiratory tract infection in young children, ranging from
upper respiratory tract infection to pneumonia or bron-
chiolitis. The clinical manifestations are very similar to
those caused by respiratory syncytial virus (RSV) infection
and difficult to be discriminated. According to the litera-
ture review, the positive rate of hMPV among respiratory
specimens obtained from patients with respiratory illnesses
ranged from 2% to 26%,1e4 indicating hMPV an important
respiratory pathogen.
Human metapneumovirus is an enveloped, single-strand
nonsegmented negative-sense RNA genome of the Para-
myxoviridae family. According to phylogenetic analysis of
sequences obtained for part of the fusion protein gene and
the complete attachment protein gene, hMPV can be clas-
sified into two major genotypes, namely A and B. Each of
the genotypes can be subclassified into two minor
subgroups, namely A1, A2, B1, and B2,5,6 defined as gen-
ogroups. Different genotypes circulate worldwide each
year. The role of different genogroups is not clear in human
infection. The information of epidemiology, genogroup
distribution and clinical characteristics of hMPV infections
in Taiwan has been quite limited. Furthermore, there are
scant reports focusing on the comparison of clinical char-
acteristics among different genogroups of hMPV infection.
We had surveyed and analyzed molecular epidemiology of
hMPV from 2005 to 2010 in northern Taiwan.7 To understand
the clinical characteristics of different hMPV genotypes
among the hospitalized children better, we conducted this
study.Materials and methods
Study design
The study was approved by the Institutional Review Board
of Chang Gung Memorial Hospital. From January 2005 to
April 2010, 3313 respiratory secretion specimens (naso-
pharyngeal secretions, bronchoalveolar lavage, or sputum)
from children, age <6 years, with suspected RSV infection
sent for RSV antigen detection in CGMH were additionally
tested for hMPV by real time-polymerase chain reaction
(RT-PCR). Demographic data, including age, sex, and
underlying diseases, were collected. Clinical information,
such as fever, cough, rhinorrhea, vomiting, diarrhea,
pharyngitis, decreased appetite, wheezing, respiratorydistress, laboratory data, chest radiograph, hospital dura-
tion, and ventilator usage, were retrospectively reviewed
from patients’ medical records. The radiological finding
was reported by a pediatric radiologist and was further
reviewed by one of the authors (H.Y. Wei). The clinical
diagnosis was reclassified according to the chest radio-
graph: pneumonia was defined as lower respiratory symp-
toms with at least one focal patch density;
bronchopneumonia was defined as increased infiltration on
both perihilar and peribronchial areas, especially for those
older than 24 months; bronchiolitis was defined as negative
finding of the chest X-ray or only slightly increased infil-
tration among patients younger than 24 months. Patients
co-infected with bacteria or respiratory viruses other than
RSV, such as influenza virus, and parainfluenza viruses
(PIVs), were excluded.
Immunofluorescent assay for detecting RSV antigen
Respiratory specimens, mostly nasopharyngeal secretions,
were collected by suction and transported to the laboratory
on ice. The specimens were diluted with 2 ml of sterile
phosphate-buffered saline (PBS), and the mucus was
broken with a Pasteur pipette. The specimens were
centrifuged at 1500 rpm (219g) for 10 minutes at 4C. The
supernatant fluid was discarded and the pellet was re-
suspended in sufficient PBS to yield a visibly turbid
suspension. The cell suspension was spotted onto a 2-well
glass slide and air dried and then fixed in cold (4C)
acetone for 10 minutes. The slides were stained with anti-
RSV monoclonal antibody conjugated with FITC (D3 Ultra
DFA Respiratory Virus Screening and ID Kit) at 37C in
a humidified chamber for 30 minutes and then washed
three times in PBS, 10 minutes each. The slides were rinsed
with PBS (pH 7.2) and then washed three times in PBS for
10 minutes, dried and mounted with mounting medium.
The slides were read under a fluorescence microscope at
400 magnification. The presence of RSV antigen was
indicated by the appearance of intracellular cytoplasmic
inclusion-like bodies or particles fluorescing an apple-green
color, in one or more respiratory epithelial cells.
RNA extraction
Viral RNAs were extracted from 140 ml of specimens using
a QIA amp Viral RNA Mini Kit (Qiagen, Valencia, CA, USA),
according to the manufacturer’s instructions. The RNA was
eluted into 30 ml elution buffer. The resulting RNA (8 ml) was
subjected to cDNA synthesis using 50 ng random hexamer
primer, 500 nM dNTPs and performed at 65C/10 minutes,
4C at least 1 minute. We applied reverse transcriptase
mixture with equal volume of reverse transcriptase buffer,
10 mM dithiothreitol, 40 units RNaseOut and 200 units
Table 1 Primers and probe sequence for detection of hMPV
Primer Sequence (50 to 30) Size Position
Forward CATAYAARCATGCTATATTAAAAGAGTCTC 162 bp 2478e2497
Reverse CCTATYTCWGCAGCATATTTGTARTCAG 2558e2537
Probe 50-FAM-AATGATGARGGTGTCACTG-MGBNFQ-30 2500e2528
354 H.-Y. Wei et al.SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad,
CA, USA) and performed at 25C for 10 minutes, 50C for
60 minutes, 85C for 5 minutes on BioMetra Thermocycler
(Biometra, Go¨ttingen, Germany).
RT-PCR detection of hMPV
RT-PCR was done using the CFX96 (Bio-Rad, Hercules, CA,
USA) system with iTaqSupermix. Amplification is performed
in a total volume of 20 ml containing each two 10 ml of
iTaqSupermix RT-PCR Master mix, 400 nM of each primer
(Table 1), 1 mM probe, 3.6 ml diethylpyrocarbonate water
and 4 ml cDNA template. The RT-PCR program was: 95C for
3 minutes, and 45 cycles with 95C for 3 seconds, and 60C
for 30 seconds.
Sequencing of fusion protein gene
The primers (Table 2) were used to generate the amplicon
of fusion protein gene segments with Pfu DNA polymerase
(Toyobo, Osaka, Japan). Briefly, the PCR master mix con-
tained 10 ml of cDNA, 10 ml PCR buffer, 200 mM dNTPs, 1 mM
MgSO4, 600 nM of each primer and 1 unit Pfu DNA poly-
merase. The PCR were perform as following conditions:
94C for 2 minutes and 40 cycles of 94C for 1 minute,
58.7C for 1 minute, 68C for 2 minutes and ended with
68C for 10 minutes. PCR products of F gene were
sequenced using BigDye Terminator v 3.1 Cycle Sequencing
Kit (Applied Biosystems, Carlsbad, CA, USA) according to
the manufacturer’s protocols. The F gene sequences were
edited and assembled using DNASTAR Lasergene 5.08
(Bioinformatics Pioneer DNASTAR, Inc., Madison, WI, USA).
The fusion protein gene (F427 or F141) was sequenced for
those with sufficient sample to determine the genogroups.
Patients with genogroup typing confirmed by F427 were
chosen for better specificity, because of the larger number
of base pairs compared to F141 (Table 2).
Statistical analysis
Significant differences between groups were determined by
Kruskal-Wallis Test for comparison of medians, and c2 or
Fisher’s exact test for comparison of proportions. AnalysesTable 2 Primer pairs for fusion protein gene sequence
Primer Sequence (50 to 30) Size Position
F427-forward ATAACACCAGCAATATC 427 bp 637e653
F427-reverse GATATGTTRATGTTGCA 1064e1038
F141-forward GCTTCAGTCAATTCAACAG 142 bp 575e593
F141-reverse CCTGCAGATGTTGGCATGT 716e697were performed using SPSS version 19.0 (SPSS Inc., Chicago,
IL, USA) for Windows. All reported p values are two-sided
and p< 0.05 was considered statistically significant.Results
A total of 725 samples from 3313 samples were positive for
hMPV, with a positive rate of 23%. F gene was sequenced in
279 isolates (279/725, 38%), and genotype Awas identified in
51% (A1, 6.1%; A2, 45%) and genotype B in 49% (B1, 19%; B2,
30%). The medical records of 152 patients who admitted to
Linko Chang Gung Memorial hospital were reviewed. Of the
152 patients, the rate of co-infection with other pathogen
was 25.7% (39/152), as shown in Fig. 1. Other viruses were
identified in 28 children (18.4%): RSV in 13, PIVs in two,
influenza A virus in three, influenza virus B in one, adenovirus
in three, rotavirus in three, and enterovirus in two. Co-
infections with bacteria were documented in 13 patients
(8.6%): bacteremia due to Staphylococcus aureus in two;
clinically significant sputumculture, including Streptococcus
pneumoniae, Haemophilus influenza, Moraxella spp., or
Klebsiella pneumoniae, in six; Mycoplasma pneumonia
infection proved by serology tests in two; urinary tract
infection due to Escherichia coli, Salmonella enteritis and
scarlet fever for one each. Two patients with coinfection of
bacteria also had RSV infection; one had Salmonella gastro-
enteritis and the other had K pneumoniae yielded from the
sputum culture. Excluding the co-infections with bacteria orFigure 1. Flow diagram showing the sample numbers,
patient numbers of hMPV identified, patient numbers of F gene
successfully sequenced, the number of co-infections with other
pathogens and the number of patients enrolled for analysis for
different genogroups.
Table 3 Clinical comparisons of the four genogroups of human metapneumovirus infection
Genotypes/genogroups
Number (%)
A B p value
A (nZ 61) A1 (nZ 14) A2 (nZ 47) B (nZ 63) B1 (nZ 19) B2 (nZ 44) A vs. B A1/A2/B1/B2
Male gender 39 (63.9) 10 (71.4) 28 (59.6) 44 (69.8) 12 (63.2) 32 (72.7) 0.312 0.571
Median age (mo) 13.5 14.1 13.5 12.9 14.1 11.3 0.457 0.529
Fever 52 (85.2) 12 (85.7) 40 (85) 51 (81.0) 18 (94.7) 33 (75.0) 0.819 0.469
Fever (d) 3.9 3.7 3.8 3.9 4.0 3.8 0.920 0.868
Temperature (median, C) 39.03 38.92 39.04 39.3 39.00 38.81 0.359 0.682
Cough 60 (98.4) 14 (100) 46 (98) 61 (96.8) 18 (94.7) 43 (97.7) 1.000 0.460
Rhinorrhea 41 (67.2) 10 (71.4) 31 (67) 50 (79.3) 16 (84.2) 34 (77.3) 0.074 0.142
Vomiting 19 (31.1) 3 (21.4) 16 (35) 26 (41.3) 6 (31.6) 20 (45.5) 0.514 0.289
Diarrhea 15 (24.6) 3 (21.4) 12 (25) 14 (22.2) 3 (15.8) 11 (25.0) 0.787 0.776
Pharyngitis 27 (44.3) 6 (42.8) 21 (46) 33 (52.4) 12 (63.2) 21 (47.7) 0.516 0.601
Wheezing 34 (55.7) 10 (71.4) 24 (50) 33 (52.4) 13 (68.4) 20 (45.4) 0.127 0.116
Respiratory distress 18 (29.5) 4 (28.5) 14 (29) 23 (36.5) 9 (47.4) 14 (31.8) 0.711 0.619
Intubation 0 (0) 0 (0) 0 (0) 1 (1.6) 0 (0) 1 (2.3) 1.000 0.641
ICU admission 2 (3.3) 0 (0) 2 (4) 3 (4.8) 1 (5.3) 2 (4.5) 1.000 0.738
Leukocyte ( 109 cells/L) 10.14 8.39 10.78 10.52 11.72 10.04 0.660 0.561
CRP (mg/L) 23.13 28.08 22.08 16.19 18.17 15.50 0.456 0.426
Admission (d) 4.98 4.21 5.24 4.98 4.94 5.00 0.211 0.607
Focal consolidation on CXR 10 (16.4) 1 (7.1) 9 (19) 5 (7.9) 2 (10.5) 3 (6.8) 0.201 0.528
RSV co-infection 4 (6.6) 1 (7.1) 3 (6.4) 7 (11.1) 1 (5.3) 6 (13.6) 0.202 0.081
Diagnosis
Bronchiolitis 42 (68.9) 12 (85.7) 30 (63.8) 53 (84.1) 15 (78.9) 38 (86.3) 0.056 0.062
Bronchopneumonia 8 (13.1) 1 (7.1) 7 (14.9) 4 (6.3) 1 (5.3) 3 (6.8) 0.224 0.493
Pneumonia 10 (16.4) 1 (7.1) 9 (19.1) 6 (9.5) 3 (15.8) 3 (6.8) 0.284 0.304
URIa 1 (1.6) 1 (2.1)
a There was only one patient in the URI group, so no p value is shown.
The statistical comparison between genotypes A and B, as well as among genogroups A1, A2, B1 and B2 were determined by the c2 test.
CRPZ C-reactive protein; CXRZ chest X-ray; ICUZ intensive care unit; RSVZ respiratory syncytial virus; URIZ upper respiratory tract
infection.
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children were collected and analyzed.
The clinical characteristics of the 124 children with
hMPV infection are shown in Table 3. The median age was
13.0 months (ranging from 8 days to 5 years and 9 months)
and 105 patients (84.7%) were younger than 2 years. The
male:female ratio was 2:1. Underlying diseases were noted
in 21 (16.9%) children and included prematurity with
gestational age <32 weeks in eight patients, congenital
heart disease in six (also had chromosome anomaly with
Dandy walker variant and mitochondrial encephalopathy,
complete agenesis of corpus callosum, Pierre Robin
syndrome, and DiGeorge syndrome for one each), gastro-
esophageal reflux disease in five, asthma in two, and
cerebral palsy and infantile spasm in one.
The three most common symptoms were cough (97.6%),
fever (83.9%), and rhinorrhea (73.4%). The mean duration
of fever was 3.9 days. Half of the children had wheezing
(54.0%) and one-third had respiratory distress with acces-
sory muscle usage (33.1%). The most common chest radio-
logic findings were increased perihilar/peribronchial
infiltration (76.6%) and focal patch were seen in 15 (12.1%)
patients. The major clinical diagnosis was bronchiolitis/
bronchopneumonia (86.3%). Oxygen therapy given by
a hood was routine in our hospital and was applied to
almost all children (86.3%). Most patients were discharged
uneventfully after a mean duration of 4.98 days.Compared with those without RSV co-infection, clinical
characteristics of the patients with RSV co-infection were
not significantly different, including demographics and
clinical manifestations (Table 4).
Of the 122 children with complete blood counts
measurements, leukopenia (white blood cells <5 109/L)
was noted in 6 patients (4.9%) and leukocytosis (white
blood cells >15 109/L) in 16 patients (13.1%). Of the 120
children with serum C-reactive protein (CRP) level
measurements, 72 (60.0%) had a serum CRP level within
normal range (<10 mg/L) and 14 (11.7%) had a CRP level
>50 mg/L.
Five children, three girls and two boys, were ever
admitted to the intensive care units. The median age was
12.18 months. Three of them have underlying disease and
included DiGeorge syndrome with ventricular septum
defect in one, Dandy walker variant with mitochondrial
encephalopathy, heart structure anomaly (coarctation of
aorta, patent ductus arteriosus, atrium, and ventricular
septum defect) in one and perinatal asphyxia sequelae in
one. The main reason for these five patients requiring
intensive care was respiratory distress with hypoxemia
under a 35% to 40% oxygen hood. One patient needed
ventilator support and was intubated. Respiratory
distress was improved by high flow mask or hood for the
other four patients. The median duration of ICU stay was
6 days.
Table 4 Comparisons of clinical characteristics between human metapneumovirus-infected children with and without
respiratory syncytial virus co-infection
Characteristics Total
(nZ 124)
% Without
RSV (nZ 113)
% RSV co-infection
(nZ 11)
% p
Male gender 82 66.1% 76 67.3% 6 54.5% 0.506
Median age (mo) 13.0 12.9 16.37 0.461
Fever 104 83.9% 95 84.1% 9 81.8% 0.789
Fever (d) 3.9 3.9 3.44 0.983
Temperature (median, C) 39.00 39.00 38.99
Cough 121 97.6% 111 98.2% 10 91.0% 1.000
Rhinorrhea 91 73.4% 82 72.7% 9 81.8% 1.000
Vomiting 45 36.3% 38 33.6% 7 63.6% 0.120
Diarrhea 29 23.4% 28 24.8% 1 9.1% 0.443
Pharyngitis 60 48.4% 57 50.4% 3 27.3% 0.307
Wheezing 67 54.0% 64 56.6% 3 27.3% 0.156
Respiratory distress 41 33.1% 36 31.9% 4 36.4% 0.726
Intubation 1 0.8% 0 0% 1 9.1% 0.087
ICU admission 5 4.0% 4 3.5% 1 9.1% 1.000
Leukocyte ( 109 cells/L) 10.33 10.37 9.95 0.172
CRP (mg/L) 19.86 20.20 8.12 0.560
Admission (d) 4.98 4.92 5.64 0.309
Focal consolidation on CXR 15 12.1% 13 11.5% 2 18.2% 0.623
Diagnosis
Bronchiolitis 95 76.6% 87 77.0% 8 72.7% 0.7161
Bronchopneumonia 12 9.7% 11 10% 1 9.1% 0.9521
Pneumonia 16 12.9% 14 12% 2 18.2% 0.8321
Upper respiratory infection 1 0.8% 1 1% 0 0% 0.7551
CXRZ chest X-ray; CRPZ C-reactive protein; ICUZ intensive care unit; RSVZ respiratory syncytial virus.
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teristics of the patients with different genotypes as well as
genogroups is shown in Table 3. No statistically significant
difference was found among the children with different
genotypes as well as genogroups of hMPV infection in terms
of demographics, clinical manifestations, and laboratory
data, although focal patch on chest radiographs was more
frequently seen in patients with genotype A than those with
genotype B (16.4% vs. 7.9%).Discussion
Results from the present study indicate that between 2005
and 2010, hMPV accounted for nearly 25% of the hospitalized
children with lower respiratory tract infection (LRTI) in
northern Taiwan. Co-infections with bacteria or other viruses
were frequently seen, with a rate of at least 25.7%. The most
common diagnosis of LRTI caused by hMPVamong hospitalized
children was bronchiolitis and accounted for 76.6%. The A2
subgroup was the most frequently observed, accounting for
more than 40%, followed by B2, whichwas consistent with the
previous report from Taiwan.8 No significant differences were
found among patients infected with different genotypes in
terms of demographics and clinical symptoms and signs.
There have been four previous studies focusing on the
correlation between genotypes and disease severity in
young children.9e13 Similar to the current study, none of
the investigators identified any significant difference
among patients infected with different genotypes in termsof clinical characteristics. Vicente et al12 indicated that
hMPV genotype A may be more virulent than genotype B.
Pitoiset et al11 found that more abnormal findings on chest
X-ray, such as bronchial wall thickening, alveolar consoli-
dation, perihilar haziness, or thoracic distension, were
noted in patients infected with serotype B than A (44% vs.
15%, p< 0.01), while in the present study, we found more
focal consolidation in patients infected with serotype A
than B. The difference between each genotype as well as
genogroup was believed to be subtle, unless the case
number is large enough. Compared to other studies, the
percentage of fever in the present study (83.9%) was
apparently higher, which may be explained by the different
inclusion criteria and only hospitalized children were
included in the present study.
The viral co-infection rate in the present study was
22.5%. Since virus isolation as well as molecular diagnostic
methods for respiratory viruses other than hMPV were not
performed for each patient, the viral co-infection rate was
apparently underestimated. No significant difference was
found between hMPV-infected children with and without
RSV co-infection in term of disease severity. Even though
RSV co-infection rate was higher for children with gen-
ogroup B2 infection, the clinical characteristics and disease
severity was not significantly different among the children
infected with different genogroups of hMPV.
Humidified oxygen is usually indicated for hospitalized
infants who are hypoxic. However, the oxygen therapy is
a routine treatment in our general ward for young patients
with tachypnea or respiratory distress, even when mild. A
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administered. Therefore, we did not take “oxygen supple-
ment” into account as one different variable for comparison.
According to the medical records, the proportion of oxygen
hood usage in the present study was 86%, which was much
higher than that in previous reports (ranging from
27e56%).11,14 Only 10 patients (8%), who presented with
marked respiratory distress, had documented saturation
data, ranging from 62% to 92%. We usually administered
oxygen supplement directly, instead of making a strict
assessment as to who needs oxygen therapy.
The major limitation of our study was its retrospective
nature. Disease severity could not be calculated, virus
detection methods were not uniform, and treatment
response could not be evaluated. Also, the study population
was limited to hospitalized children and those with respi-
ratory specimens sent for RSV antigen detection, making
the estimation of incidence rate and the perspective of
disease spectrums of hMPV infection in children unobtain-
able. In addition, RSV was the most common co-infection
pathogen in the current study (8.6%, 13/152). The higher
percentage could be explained by RSV antigen test being
the only test performed for each patient. We excluded
pathogens other than RSV because the samples were from
patients with a clinical picture of “RSV infection-like”, and
thus selection bias cannot be avoided. Therefore, we
further compared the variables between those with and
without RSV coinfection, such as fever, wheezing, and
respiratory distress, and found that there was no significant
difference, regardless of dual infection of RSV/hMPV.
In conclusion, hMPV is an important pathogen causing
LRTI among hospitalized children. Mix infection with other
viruses or bacteria is common. Even though there are two
different genogroups and four genotypes of hMPV, no
statistically significant differences was noted in patients
infected with different genogroups or genotypes of hMPV in
terms of demographics and clinical symptoms and signs.
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